Incanthera Company
Incanthera Ltd. develops cancer treatment drugs. Its ICT-2588 is a lead compound that is activated within solid tumours by a specific matrix metalloprotease enzyme. The company was incorporated in 2010 and is based in Liverpool, United Kingdom.
Headquarters:
Liverpool, Liverpool, United Kingdom
Founded Date:
2010
Estimated Revenue:
£780 000 - £7 800 000
Industry:
PharmTech